GSK's Strategic $10.6 Billion Acquisition of Nuvalent Enhances Oncology Focus
In a significant move, GSK has announced its agreement to acquire Nuvalent for $10.6 billion, further solidifying its commitment to expanding its oncology portfolio.
Editorial Staff 16 days ago